7:01AM NuPathe announces that FDA accepted co's migraine path NDA resubmission for filing (PATH) 3.87 : Co announced that its New Drug Application (NDA) resubmission for its migraine patch (NP101) has been accepted for filing by the FDA. NuPathe has received a Prescription Drug User Fee Act (PDUFA) date, the target date for the FDA to complete its review of the NDA, of January 17, 2013.
Market Data 
Markets 
AI
